Company profile
VOGENX, INC.
NASDAQ:VOGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIZAGLIFLOZIN | phase2 | — | 3 | completed, not_yet_recruiting |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05721729 | phase2 | completed | 2023-06-23 | 2024-05-01 | Vogenx, Inc. | Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions |
| NCT07760961 | phase2 | not_yet_recruiting | 2026-10-01 | 2027-10-01 | Vogenx, Inc. | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia |
| NCT05541939 | phase2 | completed | 2022-09-13 | 2023-02-17 | Vogenx, Inc. | Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects |
FDA applications (0)
No records yet.